Despite substantial progress in the past two decades, cancer remains the leading cause of death by disease in US children between 1 and 15 years of age. Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and cure rates are approaching ~ 80% today. Unfortunately, 20% of children with ALL are not cured with current therapy, making the number of cases of relapsed ALL greater than the total number of new cases of most childhood cancers. Previous work has established that de novo drug resistance is a primary cause of treatment failure in childhood ALL. However, the genomic determinants of drug resistance remain poorly defined. The research supported by this MERIT award has focused on elucidating the genomic determinants of inter-patient differences in drug response in children with ALL, leading to a number of new insights into the pharmacogenomics of childhood ALL. Our scientific aims are focused on some of the most widely used antileukemic agents, thiopurines and glucocorticoids (with complementary studies of L- asparaginase and vincristine).
The first aim i s to identify genes that influence the response to thiopurines (mercaptopurine, thioguanine), using genomewide approaches for gene expression analyses of ALL cells, and SNP analyses of germline and ALL cell DNA to identify SNPs and copy number variations (CNVs) that are significantly related to drug sensitivity and response. Studies in Aim 2 are designed to elucidate these pharmacogenomic traits in T-ALL, a less common subtype that is more resistant to curative chemotherapy, and compare these findings to B-lineage ALL. Once we identify these genes or genome abnormalities (SNPs, CNVs) influencing ALL drug resistance and treatment response, we perform biochemical and genomic studies to determine the mechanism by which these genes or their variants influence the sensitivity of ALL cells to these chemotherapeutic agents. In the continuation of this research program, we are extending our findings from the last 4 years of funding by exploiting new genomewide strategies to identify genomic determinants of drug response (e.g., 1 million SNP arrays, gene expression arrays, mIRNA arrays), to determine whether CNVs or specific mlRNAs modify the expression of genes and thereby alter the sensitivity of ALL cells to these chemotherapeutic agents. Our preliminary findings have indeed revealed specific mlRNAs that influence the sensitivity of ALL cells to these agents, and we have also recently discovered that specific CNVs in ALL cells can significantly influence drug resistance. The continuation of these studies will provide important new insights into the genomic determinants of treatment failure and point to novel targets for developing strategies to overcome drug resistance in childhood ALL.

Public Health Relevance

Pharmacogenomics has great potential to improve public health by minimizing drug-induced side events and improving treatment effectiveness. Acute lymphoblastic leukemia (ALL) the most common cancer in children, serves as a paradigm for a chemotherapy-sensitive malignancy. By capitalizing on the genomic studies which we have already conducted in children with ALL, and exploiting new genomewide technologies, we will define genomic polymorphisms that can be used to design less toxic and more efficacious cancer treatment regimens.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37CA036401-29
Application #
8266478
Study Section
Special Emphasis Panel (NSS)
Program Officer
Wu, Roy S
Project Start
1984-07-01
Project End
2015-05-31
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
29
Fiscal Year
2012
Total Cost
$656,917
Indirect Cost
$252,136
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Diouf, Barthelemy; Devaraju, Prakash; Janke, Laura J et al. (2016) Msh2 deficiency leads to dysmyelination of the corpus callosum, impaired locomotion, and altered sensory function in mice. Sci Rep 6:30757
Walsh, Kyle M; Whitehead, Todd P; de Smith, Adam J et al. (2016) Common genetic variants associated with telomere length confer risk for neuroblastoma and other childhood cancers. Carcinogenesis 37:576-82
Liu, Chengcheng; Yang, Wenjian; Devidas, Meenakshi et al. (2016) Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia. J Clin Oncol 34:2133-40
Deng, L; Xu-Monette, Z Y; Loghavi, S et al. (2016) Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium. Leukemia 30:361-72
Liu, C; Yang, W; Pei, D et al. (2016) Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait. Clin Pharmacol Ther :
Vora, Ajay; Andreano, Anita; Pui, Ching-Hon et al. (2016) Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy. J Clin Oncol 34:919-26
Paugh, Steven W; Coss, David R; Bao, Ju et al. (2016) MicroRNAs Form Triplexes with Double Stranded DNA at Sequence-Specific Binding Sites; a Eukaryotic Mechanism via which microRNAs Could Directly Alter Gene Expression. PLoS Comput Biol 12:e1004744
Karol, Seth E; Mattano Jr, Leonard A; Yang, Wenjian et al. (2016) Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia. Blood 127:558-64
Pui, Ching-Hon; Pei, Deqing; Coustan-Smith, Elaine et al. (2015) Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncol 16:465-74
Diouf, Barthelemy; Crews, Kristine R; Lew, Glen et al. (2015) Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA 313:815-23

Showing the most recent 10 out of 243 publications